N/A N=553 Testing the Implementation of EIT-4-BPSD
Dementia · Behavioral and Psychological Symptoms of Dementia (BPSD)
Primary: Physical Function as Determined by Barthel Index — 35.82; 31.36; 33.63; 33.93 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=276 Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
Heart Failure With Reduced Ejection Fraction
Primary: Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20 — -0.239; 0.207 mL/min/kg — p=0.13
N/A N=11 Post Stroke Walking Kinematics Using the Honda Walking Assist Robotic Exoskeleton
Stroke
Primary: Gait Kinematics — 55.9; 57.8; 58.3; 56.6 degrees — p=0.973
N/A N=20 "FEXIS": (Feasibility of an Extended Wear CSII Set in Participants With T1DM)
Diabetes Mellitus, Type 1 · Type 1 Diabetes · Type 1 Diabetes Mellitus
Primary: Rate of Infusion Set Survival at End of Day 7 — 36 Achilles infusion sets
Phase 4 N=421 Pain Increases After Shoulder Injection
Shoulder Pain
Primary: Incidence of a Flare Reaction — 44; 8; 149; 191 Person-visits
Phase 3 N=184 Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke
Smoking · HIV
Primary: Number of Participants With 7-day Point Prevalence Abstinence at 36 Weeks — 5; 4; 1; 5 Participants
Phase 3 N=112 A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
HOCM, Hypertrophic Obstructive Cardiomyopathy
Primary: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 — 10; 43 Participants — p=<0.0001
N/A N=106 Endoscopic vs. Suction Device Calibration in Sleeve Gastrectomy
Gastrectomy · Obesity
Primary: Number of Staple Load Firings — 5.26; 5.42 Number of staples
Phase 3 N=511 Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
Hyperphosphatemia
Primary: Change in Serum Phosphorus (s-P) Level From Baseline to Week 4. — -0.84; -0.19 mg/dL — p=0.0004
Phase 1 N=38 Continuous Infusion of rhIL-15 for Adults With Advanced Cancer
Lymphoma · Carcinoma
Primary: Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin-15 (rhIL-15) for 10 Day Dosing — 2 mcg/kg/day
Phase 3 N=770 Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
Locally Advanced Cervical Cancer
Primary: Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression — NA; NA Months…
Phase 2 N=28 Duvelisib to Combat COVID-19
COVID-19
Primary: Overall Survival as Measured by Number of Participants Alive Through 28 Days — 10; 8 Participants
Phase 4 N=20 A Pilot Study: High Versus Low Oxytocin Dosing for Induction of Labor in Pregnant Patients With Obesity
Pregnant Patients With Obesity
Primary: Number of Participants Delivered by Cesarean — 3; 3 Participants
N/A N=156 Tough Talks: A Disclosure Intervention for HIV+ Young Men Who Have Sex With Men (YMSM)
Hiv · HIV/AIDS · Disclosure
Primary: Number of Participants With Suppressed Viral Load — 29; 31; 30 Participants
N/A N=37 The Influence of Bone Allograft Particle Sizes on the Quantity and Quality of New Bone Formation in Grafted Extraction Sockets and Edentulous Ridges
Alveolar Ridge Augmentation · Alveolar Ridge Preservation
Primary: New Bone Formation (in %) With the Use of Small vs. Large Particle Bone Allografts — 17.3; 25.9; 41.0; 31.4 % of new bone